-
.
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
-
.
and parents who refuse to vaccinate their children should consider what they are doing to other young kids in their communities. .
the youngest claimant was aged 20, and the eldest aged 89, while the average policy duration at claim stage was 10 years. .